Company Overview and News

29
Market Live: Sensex, Nifty Bank extend rally on further recovery in Asian peers

2018-06-20 moneycontrol
Market Update: The market extended gains on further recovery in Asian counterparts that were hit by elevated fears of a trade war between the US and China.
OPTOCIRCUI 500325 RELIANCE BRIGADE MS.PRE MS.PRF 512573 532418 MS.PRG MS.PRA BHRQY 532215 JUSTDIAL 535648 521070 532483 AXISBANK RIGD MS BHARTIARTL 590073 WHEELS RLNIY 532929 AXB AVANTI CNRYY AXBKY 532454 AXBA MS.PRI MS.PRK ALOKTEXT 532391 CANBK JSTQY ANDHRABANK

29
Market Live: Sensex, Nifty Bank up 100 pts; Asia trades higher except Shanghai

2018-06-20 moneycontrol
BHEL in focus: Nomura has upgraded state-owned power equipment maker BHEL to Neutral with a target price at Rs 86 per share as the stock price seems to have has bottomed out.
OPTOCIRCUI 500325 RELIANCE BRIGADE MS.PRE MS.PRF 532418 MS.PRG MS.PRA BHRQY 532215 JUSTDIAL 535648 521070 532483 AXISBANK RIGD MS BHARTIARTL 590073 WHEELS RLNIY 532929 AXB CNRYY AXBKY 532454 AXBA MS.PRI MS.PRK ALOKTEXT 532391 CANBK JSTQY ANDHRABANK

36
Market Live: Sensex extends losses amid trade war woes; IOC, HPCL, BPCL dip 3%

2018-06-19 moneycontrol
Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental abbreviated new drug application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina.
LIBERTSHOE 523768 500325 GUJBOROS RELIANCE KAJARIACER 532418 BHRQY GLKQY 532215 JUSTDIAL CMQMY 500470 535648 533407 AXISBANK RIGD 500233 CUMMINSIND BHARTIARTL 500790 NSZTY RLNIY SBAZ GLENMARK AXB 502219 IBN NESTLEIND HEXAWARE 539302 532129 AXBKY POWERMECH 532454 BOROSIL AXBA 500480 ICICIBANK TTST 532296 TATASTEEL TATLY 532174 CNOVAPETRO 526596 JSTQY ANDHRABANK

1
22 GMs to be elevated as state bank EDs soon

2018-06-18 freepressjournal.in
Mumbai : The Banks Board Bureau (BBB), the advisory body formed by the government for selection of candidates for top level board appointments, has recommended names of 22 general managers to be elevated as executive directors at various state banks.
532121 532480 532418 ALBK DENABANK ANDHRABANK

0
BoB in talks to sell Malaysian JV

2018-06-16 freepressjournal.in
Mumbai : Bank of Baroda along with Indian Overseas Bank and Andhra Bank are in advanced discussions with a possible buyer to sell their stake in Malaysian joint venture —India International Bank (Malaysia) Berhad, two sources involved with the negotiations said.
532388 IOB 532418 ANDHRABANK

0
Andhra Bank moves NCLT to recover Rs 4,000-crore Sterling Biotech dues

2018-06-12 freepressjournal.in
Mumbai : The National Company Law Tribunal (NCLT) on Monday admitted an insolvency plea filed by Andhra Bank against Sterling Biotech, seeking recovery of Rs 4,000 crore in dues.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

11
Of leadership crunch and low pay: The talent crisis in public sector banks

2018-06-08 moneycontrol
At a time when a majority of the banking sector is fraught with bleeding balance sheets, at least four public sector banks remain headless.
INDIANB UDBKL IDBI 532418 UBLS 532814 SYNDIBANK 532121 532461 532483 UBLA SBAZ 500116 IBN 532505 CNRYY ICICIBANK 532276 PNJZY 532174 PNB UCOBANK CANBK DENABANK ANDHRABANK

22
Market Update: Nifty pharma sprints ahead as Sun Pharma zooms 8%; Bajaj Finance hits new 52-week high

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday afternoon but managed to regained some lost ground with the Nifty trading lower by 11 points at 10,757 and the Sensex shed 41 points at 35,422.
500408 IOB 500325 AUROPHARMA FSL RELIANCE 532418 TCHQY 532755 511389 VIDEOIND TTNQY CADILAHC 532388 532321 500470 532540 532461 RIGD BJJQY 500570 TATAMOTORS RLNIY 500034 UBNC 532809 524804 VTUWY CDLYY 539207 TECHM 533269 BAJFINANCE TTST PNJZY TATASTEEL TATLY SINTEX ARBQY 502742 TATAELXSI TCS PNB MANPASAND WABAG ANDHRABANK TTM

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...